ODYSSEY COMBO II: Alirocumab Significantly Improves Cholesterol Levels in Patients with High CV Risk

Article Information

DOI 
http://dx.doi.org/10.1177/155989771427003
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2014 MD Conference Express®

Author Information

  1. Nicola Parry
  1. Christopher P. Cannon, MD
    1. Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA
View Full Text

Article usage

AbstractFullPDF
Apr 20157491
May 2015700
Jun 2015611
Jul 20151701
Aug 2015411
Sep 2015300
Oct 2015133
Nov 2015100
Total113147

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
ODYSSEY COMBO II: Alirocumab Significantly Improves Cholesterol Levels in Patients with High CV Risk
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Cardiology
Lipid Disorders
Cardiology Clinical Trials
Cardiology
Lipid Disorders
Cardiology Clinical Trials